Principal Investigator
Hadar Lev-Tov
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20221271
Clinical Trial Summary
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants with Moderate to Severe Hidradenitis Suppurativa
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other